Literature DB >> 9740435

Malignancy may adversely influence the quality and behaviour of oocytes.

L Pal1, L Leykin, J L Schifren, K B Isaacson, Y C Chang, N Nikruil, Z Chen, T L Toth.   

Abstract

A case series of eight cycles of in-vitro fertilization (IVF) in five women diagnosed with malignant disorders is presented. These patients chose to defer definitive treatment for a chance for preservation of potential fertility. The response of these patients to ovarian stimulation, and the outcome, was compared with 17 IVF cycles in 12 age-matched patients with isolated tubal infertility. An apparent adverse influence of malignant disease on the quality and behaviour of oocytes was observed. Despite a comparable total number of oocytes per cycle in the two groups, a significantly reduced percentage of mature oocytes was retrieved per cycle from patients with malignant diseases. The oocytes from patients with malignant disorders were of a poorer quality and exhibited a significantly impaired fertilization rate compared to the controls. We propose that neoplastic processes, irrespective of the site or cell of origin, may have a detrimental impact on the biology of oocytes, an effect akin to that seen on spermatozoa in men with certain malignancies.

Entities:  

Mesh:

Year:  1998        PMID: 9740435     DOI: 10.1093/humrep/13.7.1837

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  18 in total

1.  Response to ovarian stimulation in patients facing gonadotoxic therapy.

Authors:  Lauren N C Johnson; Katherine E Dillon; Mary D Sammel; Brenda L Efymow; Monica A Mainigi; Anuja Dokras; Clarisa R Gracia
Journal:  Reprod Biomed Online       Date:  2013-01-19       Impact factor: 3.828

2.  Effect of cancer on ovarian function in patients undergoing in vitro fertilization for fertility preservation: a reappraisal.

Authors:  I Levin; B Almog
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

3.  Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors.

Authors:  Nicole Noyes; Patty Ann Labella; James Grifo; Jaime M Knopman
Journal:  J Assist Reprod Genet       Date:  2010-05-18       Impact factor: 3.412

4.  The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.

Authors:  Jiangxue Qu; Yuehan Li; Shujie Liao; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Oocyte retrieval outcomes among adolescent transgender males.

Authors:  Hadar Amir; Asaf Oren; Emilie Klochendler Frishman; Onit Sapir; Yoel Shufaro; Anat Segev Becker; Foad Azem; Avi Ben-Haroush
Journal:  J Assist Reprod Genet       Date:  2020-05-20       Impact factor: 3.412

6.  Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients.

Authors:  Mary E Sabatini; Ann M Wolkovich; Eric A Macklin; Diane L Wright; Irene Souter; Thomas L Toth
Journal:  J Assist Reprod Genet       Date:  2010-11-24       Impact factor: 3.412

Review 7.  Fertility Management for the Hemato-Oncologist.

Authors:  Parathan Karunakaran; Pankaj Malhotra; Deepesh Lad
Journal:  Indian J Hematol Blood Transfus       Date:  2017-10-11       Impact factor: 0.900

8.  Impact of breast cancer on anti-mullerian hormone levels in young women.

Authors:  H I Su; S W Flatt; L Natarajan; A DeMichele; A Z Steiner
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

Review 9.  Female fertility and colorectal cancer.

Authors:  Constantine P Spanos; Apostolos Mamopoulos; Apostolos Tsapas; Theodore Syrakos; Dimitris Kiskinis
Journal:  Int J Colorectal Dis       Date:  2008-05-06       Impact factor: 2.571

10.  Ovarian response to controlled ovarian hyperstimulation in women with cancer is as expected according to an age-specific nomogram.

Authors:  Marta Devesa; Francisca Martínez; Buenaventura Coroleu; Ignacio Rodríguez; Clara González; Pedro Nolasco Barri
Journal:  J Assist Reprod Genet       Date:  2014-02-04       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.